ClinicalTrials.gg
Active, not recruitingNCT07011459Updated Oct 16, 2026

The Cooking for Health Optimization and Disease Prevention (CHOP) Trial

An interventional study of Cooking class and Standard of care in Cardiovascular Diseases, sponsored by Tulane University. Active, not recruiting at 2 sites in United States. Open to participants aged 55 Years to 120 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Tulane University · Not applicable, Interventional, and Prevention

How we know

Updated Oct 16, 2026Now Active, not recruitingPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
97
Allocation
Randomized
Ages
55 Years to 120 Years
Sex
All
01

Study summary

Poor nutrition-related diseases disproportionately impact seniors and racial/ethnic minorities who are more likely to experience disparities in proper nutrition. Culinary medicine is a new evidence-based educational approach that blends the art of food and cooking with the science of medicine. Recently, culinary medicine is proposed by the 2020-2030 Strategic Plan for NIH Nutrition Research and national 'Food is Medicine (FIM)' Movement as potential solutions for improving healthy eating, creating social and emotional connections, and nutrition-related health equity. Built upon the well-established community teaching kitchen at The Goldring Center for Culinary Medicine (GCCM) at Tulane University and nearly 10 years of experience in delivering culinary education of Mediterranean diet (MedDiet), the investigators will conduct a randomized controlled trial (RCT) to test the feasibility and effectiveness of 3-month community teaching kitchen-based culinary education of MedDiet on improving cardiometabolic and mental health among racially and ethnically diverse seniors.

Read the detailed description

The study is designed as a two-arm parallel-group randomized controlled trial (RCT). The interventions in the two groups are described as below:

i) Culinary intervention group (n=48): The interventions include the teaching-kitchen based structured, hands-on culinary education classes.

ii) Usual diet control group (n=48): Participants randomized to the usual diet group will not receive culinary education classes, while they will continue to receive clinical care recommendations from their physician(s).

02

Conditions studied

  • Cardiovascular Diseases

Keywords

  • Culinary
  • Cardiometabolic health
  • Mental health
  • Mediterranean Diet
  • Nutrition
03

In context

Cardiovascular Diseases

5,375 studies on the registry are indexed under Cardiovascular Diseases; 940 are open to participants now.

This study's enrollment of 97 is close to the median of 100 across 3,086 interventional studies indexed under Cardiovascular Diseases.

Browse Cardiovascular Diseases studies →

Lead sponsor

Tulane University is the lead sponsor of 96 studies on the registry; 23 are open to participants now.

Of its 9 completed or terminated interventional studies of FDA-regulated products, 5 (56%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
55 Years to 120 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 55 years or older
  • English speaking
  • Ability to provide .

Exclusion criteria

Exclusion Criteria:

  • Medical history of cardiovascular disease (CVD) or cancer.
  • Food allergies including, but not limited to, milk, eggs, shellfish, nuts, wheat or gluten, and soy.
  • Special diets including, but not limited to, Mediterranean, veganism, vegetarianism, gluten-free, and the ketogenic diet.
  • Current use of medications that could affect blood glucose and lipids levels including, but not limited to, insulins (Humalog, Novolog, insulin detemir, etc.), anti-diabetic medications (metformin, sulfonylureas, meglitinides, etc.), Ozempic. HAART, and beta blockers.
  • No children are involved.
  • No other vulnerable subjects will be involved.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
97 participants (actual)

Study arms

  • Active comparator
    Culinary intervention group

    The interventions include the teaching-kitchen based structured, hands-on culinary education classes.

    Behavioral: Cooking class

  • Placebo comparator
    Usual diet control group

    Participants randomized to the usual diet group will not receive culinary education classes, while they will continue to receive clinical care recommendations from their physician(s).

    Other: Standard of care

Interventions

  • BehavioralCooking class

    3-month community teaching kitchen-based culinary education of MedDiet

  • OtherStandard of care

    Participants will continue to receive clinical care recommendations from their physicians

06

What researchers measure

Primary outcomes

  1. Change in blood pressure measurements

    The investigators will measure the change in blood pressure from baseline visit 1 to visit 3. The average of 3 blood pressure readings will be taken. They will be measured at baseline visit and at 3 months visit.

    Time frame: Baseline, 3 months

  2. Change in blood glucose measurements

    The investigators will measure the change in blood glucose. The fasting blood glucose will be measured at baseline and at 3 months visit. A continuous glucose monitoring (CGM) device will be used as well to measure the change in blood glucose.

    Time frame: Baseline, 3 months

  3. Change in blood lipid profile measurements

    The investigators will measure the change in blood lipid profile. The blood lipid profile will be measured at baseline and at 3 months visit.

    Time frame: Baseline, 3 months

Secondary outcomes

  1. Change in cognitive function measured using the Montreal Cognitive Assessment (MoCA)

    The investigators will measure the change in cognitive function using the Montreal Cognitive Assessment. It is a screening tool used to assess cognitive function. A higher score indicates less severe cognitive impairment. The grading scale for the MoCA is as follows: 0-9: Severe cognitive impairment 10-17: Moderate cognitive impairment 18-25: Mild cognitive impairment 26-30: Normal cognitive function This will be measured at baseline visit and at 3 months visit.

    Time frame: Baseline, 3 months

  2. Depression severity assessment using the PHQ-9 (Patient Health Questionnaire)

    The investigators will assess the depression severity using the PHQ-9 (Patient Health Questionnaire) It is a self-reporting scoring system which assigns points to each question based on the frequency of reported symptoms, with a total score ranging from 0 to 27. The total score can then be used to determine the possible level of depression severity. The higher the score, the more severe depression level will be. 0-4 points: None to minimal depression. 5-9 points: Mild depression. 10-14 points: Moderate depression. 15-19 points: Moderately severe depression. 20-27 points: Severe depression. This will be measured at baseline visit and at 3 months visit.

    Time frame: Baseline, 3 months

  3. Loneliness severity assessment using the UCLA Loneliness Scale Version 3 (UCLA-LS)

    The investigators will assess the loneliness severity using the UCLA Loneliness Scale Version 3 (UCLA-LS). It is a self-reporting questionnaire used to measure an individual's feelings of loneliness. It's scored by combining the total of responses to 20 questions, where higher scores generally indicate greater feelings of loneliness. The interpretation of scores often uses a categorization based on the total score, with scores above 43 generally indicating a high degree of loneliness. Low Loneliness: Total score \< 28. Moderate Loneliness: Total score 28-43. High Loneliness: Total score \> 43. This will be measured at baseline visit and at 3 months visit.

    Time frame: Baseline, 3 months

  4. Social Anxiety Disorder assessment using the Severity Measure for Social Anxiety Disorder (Social Phobia Scale for Adults) questionnaire

    The investigators will assess Social Anxiety Disorder using the Severity Measure for Social Anxiety Disorder (Social Phobia Scale for Adults). It is a 10-item questionnaire, used to assess social anxiety (social phobia) in adults. Total Score Range: 0-40. Interpretation: Higher scores correlate with more severe social phobia symptoms. Cut-off Score: 24 or above may indicate a presence of non-generalized social phobia. This will be measured at baseline visit and at 3 months visit.

    Time frame: Baseline, 3 months

  5. Mediterranean eating pattern assessment using the Mediterranean Diet Adherence Screener (MEDAS) questionnaire

    The investigators will assess the Mediterranean eating pattern using the Mediterranean Diet Adherence Screener (MEDAS) questionnaire. It is used to assess how someone's diet aligns with a traditional Mediterranean eating pattern. A higher score means better adherence. 0-4 points: Generally considered low adherence. 5-9 points: Considered moderate to fair adherence. 10-14 points: Indicates good or very good adherence. This will be measured at baseline visit and at 3 months visit.

    Time frame: Baseline, 3 months

07

Study locations

2 sites
  • The Goldring Center for Culinary Medicine
    New Orleans, Louisiana 70112, United States
  • Tulane Weatherhead School of Public Health and Tropical Medicine
    New Orleans, Louisiana 70112, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Nov 2026, 16 months after the start.

Of 1,081 non-industry interventional studies with no phase under Cardiovascular Diseases, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 48. This study's planned 16 months is below that.

Counting every sponsor, half of 1,220 studies reached it within 26 months; a quarter within 12 and three quarters within 49.

Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Dec 2026 → Nov 2026 and completion Dec 2026 → Nov 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2025
First posted
Jun 8, 2025
StartActual
Jul 7, 2025
Primary completionEst.
Nov 2026was Dec 2026
CompletionEst.
Nov 2026was Dec 2026
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 16, 2026
Primary completion
Dec 2026→Nov 2026
Oct 16, 2026
Study completion
Dec 2026→Nov 2026
Oct 16, 2026
Enrollment
96 (estimated)→97 (actual)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    Recruiting→Active, not recruiting
    Primary completion Dec 2026→Nov 2026
    Study completion Dec 2026→Nov 2026
    Enrollment 96 (estimated)→97 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07011459
Lead sponsor
Tulane University
Collaborators
Humana Foundation
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jul 7, 2025
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Lu Qi, PhD, MD
principal investigator · Tulane University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion